An inhibitor of FLT3 known as ASP2215 showed good clinical activity in FLT3-mutated patients with relapsed or refractory acute myeloid leukemia (AML).

A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.

Early trial results suggest that a copper-depleting agent may create an inhospitable environment for tumor progression in patients with breast cancer.

The prostate cancer drug enzalutamide has shown activity in women with advanced triple-negative breast cancer whose tumors express the androgen receptor.

Data from the LUX-Lung 8 trial showed afatinib outperformed erlotinib with regard to both progression-free and overall survival in squamous cell lung cancer.

A new agent, AZD9291, showed promising clinical activity and progression-free survival in a study of patients with advanced stage, EGFR mutation-positive NSCLC.

Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.


Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.